Hemogenyx Pharmaceuticals to present Chimeric Bait Receptor platform at 6th Macrophage-Directed Therapies Summit in Boston, Oct 1-3, 2024.

Hemogenyx Pharmaceuticals, a clinical-stage biopharmaceutical company, will present at the 6th Macrophage-Directed Therapies Summit in Boston, Oct 1-3, 2024. The company will showcase its Chimeric Bait Receptor (CBR) platform, an advanced immunotherapy for treating rare cancers and viral infections. The summit aims to bring together cell therapy developers, collaborators, and investors.